Practical strategies for management of hypertension in the elderly

Geriatrics

Volumn 64, Issue 10, 2009, Pages 10-19

  Gibson, Maria V ^a   Fritz, Julie ^b   Kachur, Vladimir ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b University of West Georgia ^*

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Adherence to therapy; Aging; Blood pressure; Combination therapy; Elderly; Resistant hypertension

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; MINOXIDIL; THIAZIDE DIURETIC AGENT;

AGED; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIABETES MELLITUS; ELDERLY CARE; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HUMAN; HYPERTENSION; KIDNEY DISEASE; LIFESTYLE MODIFICATION; MONOTHERAPY; ORGAN INJURY; PATIENT COMPLIANCE; PATIENT MONITORING; PREVALENCE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SOCIOECONOMICS; SYSTOLIC HYPERTENSION; WEIGHT GAIN;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIET, SODIUM-RESTRICTED; EXERCISE; HEALTH PROMOTION; HEALTH SERVICES FOR THE AGED; HEALTH STATUS; HUMANS; HYPERTENSION; LIFE STYLE; PATIENT EDUCATION AS TOPIC; SMOKING CESSATION; UNITED STATES;

EID: 77953626604     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. United Nations. Department of Economic and Social Affairs. Population Division. World Population Ageing: II. 1950-2050. Magnitude and speed of population ageing. New York: United Nations; 2002: 11-13. www.un.org/esa/ population/publications/ worldageing19502050/pdf/80chapterii.pdf. Accessed September 3, 2009.
2. Lloyd-Jones D, Adams R, Carnethon M, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):480-486.
3. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005;294(4):466-472.
4. World Health Organization. The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva: World Health Organization; 2002. www.who. int/whr/2002/en/index.html. Accessed September 3, 2009.
5. Martiniuk AL, Lee CM, Lawes CM, et al. Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region. J Hypertens. 2007;25(1):73-79.
6. Gudmundsson LS, Johannsson M, Thorgeirsson G, Sigfusson N, Sigvaldason H, Witteman JC. Hypertension control as predictor of mortality in treated men and women, followed for up to 30 years. Cardiovasc Drugs Ther. 2005;19(3):227-235.
7. Mulrow CD, Lau J, Cornell J, Brand M. Pharmacotherapy for hypertension for the elderly. Cochrane Database Syst Rev. 1997;(4):CD000028. doi:10.1002/14651858.
8. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-1898.
9. Reitz C, Tang MX, Manly J, Mayeux R, Luchsinger JA. Hypertension and the risk of mild cognitive impairment. Arch Neurol. 2007;64(12):1734-1740. (Pubitemid 350254935)
10. Knecht S., Wersching H, Lohmann H, Berger, K, Ringelstein EB. How much does hypertension affect cognition? Explained variance in cross-sectional analysis of non-demented community-dwelling individuals in the SEARCH study. J Neurol Sci. 2009;283(1-2):149-152.
11. McGuinness B, Todd S, Passmore P, Bullock R. The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without prior cerebrovascular disease. Cochrane Database Syst Rev. 2006;(2):CD004034.
12. Huang CQ, Dong BR, Zhang YL, Wu HM, Liu OX, Flaherty JH. Cognitive impairment and hypertension among Chinese nonagenarians and centenarians. Hypertens Res. 2009;32(7):554-558.
13. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111(5):697-716.
14. Williams B, Lindholm LH, Sever P. Systolic pressure is all that matters. Lancet. 2008;371(9631):2219-2221.
15. Mancia G, De Backer G, Dominiczak A, et al; the task force for the management of arterial hypertension of the European Society of Hypertension; the task force for the management of arterial hypertension of the European Society of Cardiology. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28(12):1462-1536.
16. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572.
17. Siscovick DS, Raghunathan TE, Psaty BM, et al. Diastolic blood pressure and the risk of primary cardiac arrest among pharmacologically treated hypertensive patients. J Gen Intern Med. 1996;11(6):350-356.
18. Fletcher AE, Beevers DG, Bulpitt CJ, et al. The relationship between a low treated blood pressure and IHD mortality: a report from the DHSS Hypertension Care Computing Project (DHCCP). J Hum Hypertens. 1988;2(1):11-15.
19. Fagard RH, Staessen JA, Thijs L, et al. On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med. 2007;167(17):1884-1891.
20. Cruickshank JM. Antihypertensive treatment and the J-curve. Cardiovasc Drugs Ther. 2000;14(4):373-379.
21. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755-1762. (Pubitemid 28269185)
22. Milchak JL, Carter BL, James PA, Ardery G. Measuring adherence to practice guidelines for the management of hypertension: an evaluation of the literature. Hypertension. 2004;44(5):602-608.
23. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51(6):1403-1419.
24. Mazzaglia G, Mantovani LG, Sturkenboom MC, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens. 2005;23(11):2093-2100.
25. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens. 2005;23(11):2101-2107.
26. Cooper LA. A 41-year-old African American man with poorly controlled hypertension: review of patient and physician factors related to hypertension treatment adherence. JAMA. 2009;301(12):1260-1272.
27. Bodenheimer T. A 63-year-old man with multiple cardiovascular risk factors and poor adherence to treatment plans. JAMA. 2007;298(17):2048-2055.
28. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997.
29. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527-1535.
30. Dickinson HO, Mason JM, Nicolson DJ, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomised controlled trials. J Hypertens. 2006;24(2):215-233.
31. Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA. 2004;292(12):1433-1439.
32. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA. 1998;279(11):839-846.
33. American Heart Association Nutrition Committee, Lichtenstein AH, Appel LJ, Brands M, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006;114(1):82-96.
34. National Collaborating Centre for Chronic Conditions. Hypertension: Management in adults in primary care: pharmacological update. London: Royal College of Physicians; 2006. www.nice.org.uk/nicemedia/pdf/HypertensionGuide. pdf. Accessed September 3, 2009.
35. Dickerson JE, Hingorani AD, Ashby MJ, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet. 1999;353(9169):2008-2013.
36. Saseen JJ, Carter BL, Brown TE, Elliott WJ, Black HR. Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. Hypertension. 1996;28(1):109-114.
37. Stergiou GS, Skeva II, Baibas NM, et al. Additive hypotensive effect of angiotensinconverting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension. J Cardiovasc Pharmacol. 2000;35(6):937-941.
38. Dickerson LM, Gibson MV. Management of hypertension in older persons. Am Fam Physician. 2005;71(3):469-476.
39. Lindholm LH, Carlberg B, Samuelsson O Should B-blockers remain first choice in the treatment of primary hypertension? A metaanalysis. Lancet. 2005;366(9496):1545-1553.
40. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372(9644):1174-1183.
41. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358(23):2433-2446.
42. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet. 2006; 368(9545):1449-1456.
43. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;(2):CD000011.
44. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev. 2004;(2):CD004804.
45. Sica DA. Chlorthalidone: has it always been the best thiazide-type diuretic? Hypertension. 2006;47(3):321-322.
46. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16(11 pt 1):925-930.